EE40 Cost-Effectiveness of GLP-1 Receptor Agonists Versus Long-Acting Insulins in Type 2 Diabetes From the Healthcare Sector Perspective: A Model-Based Analysis Using Real-World DataWY YaoElsevier BV2022DOI 10.1016/j.jval.2022.09.293
EE406 Colorectal Cancer Screening - Benefit-Harm and Cost-Effectiveness Analysis of Population-Wide Screening Strategies in AustriaB JahnElsevier BV2022DOI 10.1016/j.jval.2022.09.652
EE406 Development of Scenarios By Health State to Measure the Quality of Life of Spinal Muscular Atrophy in the General PopulationKim, A.Y.Elsevier BV2023DOI 10.1016/j.jval.2023.03.707
EE404 Forecast of Social and Economic Burden of HIV-Infection in Russia in Different Scenarios of Anti-HIV Policy up to 2035NA AvxentyevElsevier BV2022DOI 10.1016/j.jval.2022.09.650
EE407 Budget Impact Analysis of the Use of Emicizumab in Prophylaxis for Severe Hemophilia A and Inhibitors in the Pediatric Population of the Dominican RepublicA MunozValue in Health2022DOI 10.1016/j.jval.2022.09.653
EE400 Comparing the Budget Impact of Selective Internal Radiation Therapy Using Y-90 Resin Microspheres Versus Drug Eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma in EnglandRF PollockElsevier BV2022DOI 10.1016/j.jval.2022.09.646